Humanigen, Inc. (HGENQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Humanigen, Inc. (HGENQ) with AI Score 46/100 (Weak). Humanigen, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune hyper-response. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Humanigen, Inc. (HGENQ) Healthcare & Pipeline Overview
Humanigen, Inc., a clinical-stage biopharmaceutical company, is focused on developing lenzilumab to treat immune hyper-response, particularly cytokine storm associated with COVID-19. Currently undergoing Chapter 11 reorganization, the company's future hinges on its pipeline and successful restructuring amidst a competitive biotechnology landscape.
Investment Thesis
Humanigen's investment thesis is highly speculative given its Chapter 11 bankruptcy filing in January 2024. Prior to this, the potential value driver was lenzilumab's success in treating cytokine storm and other inflammatory conditions. The completion of a Phase 3 study for COVID-19-related cytokine storm and ongoing Phase 2/3 NIH-sponsored study were key milestones. However, the bankruptcy introduces substantial risk, as the company's ability to continue operations and develop its pipeline is now contingent on successful reorganization and securing additional funding. The market capitalization of $0.00B reflects this high level of uncertainty.
Based on FMP financials and quantitative analysis
Key Highlights
- Lenzilumab completed a Phase 3 study for COVID-19-related cytokine storm, though its efficacy and commercial potential are now uncertain due to the bankruptcy.
- Humanigen filed for Chapter 11 bankruptcy on January 3, 2024, significantly impacting its financial stability and future operations.
- The company's market capitalization is $0.00B, reflecting the high risk associated with its current financial situation.
- Lenzilumab's development was also focused on other inflammatory conditions, including acute Graft versus Host Disease, eosinophilic asthma, and rheumatoid arthritis, expanding its potential therapeutic applications.
- The company's pipeline included two other Humaneered monoclonal antibodies, ifabotuzumab and HGEN005, targeting EphA3 and EMR1, respectively, for treating eosinophilic diseases, but their development is now uncertain.
Competitors & Peers
Strengths
- Proprietary Humaneered antibody technology.
- Clinical data supporting lenzilumab's efficacy (prior to bankruptcy).
- Experienced management team (prior to bankruptcy).
- Focus on unmet medical needs in immunology.
Weaknesses
- Chapter 11 bankruptcy.
- Limited financial resources.
- Dependence on lenzilumab.
- Small number of employees (6).
Catalysts
- Ongoing: Chapter 11 reorganization process.
- Upcoming: Potential emergence from bankruptcy.
- Upcoming: Securing additional funding.
- Upcoming: Potential partnerships or collaborations.
Risks
- Ongoing: Chapter 11 bankruptcy.
- Potential: Failure to reorganize and emerge from bankruptcy.
- Potential: Dilution of existing shareholders.
- Potential: Loss of key personnel.
- Potential: Regulatory setbacks.
Growth Opportunities
- Lenzilumab Expansion: Prior to bankruptcy, expanding the use of lenzilumab beyond COVID-19 to other inflammatory conditions like acute Graft versus Host Disease, eosinophilic asthma, and rheumatoid arthritis represented a significant growth opportunity. Each of these indications represents a substantial market, but the company's ability to pursue these opportunities is now uncertain. The timeline for potential market entry is dependent on successful reorganization and securing funding.
- Pipeline Development: The development of ifabotuzumab and HGEN005, the company's other Humaneered monoclonal antibodies, offered potential for future growth. These antibodies target EphA3 and EMR1, respectively, and are aimed at treating eosinophilic diseases. However, the progress of these programs is now uncertain due to the bankruptcy, and any potential market entry is likely several years away.
- Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical companies or research institutions could have provided Humanigen with access to additional resources and expertise. However, the bankruptcy may make it difficult to attract potential partners, as the company's long-term viability is now in question. Any potential collaborations would likely be contingent on successful reorganization.
- CAR-T Therapy: Exploring the use of lenzilumab in conjunction with CD19-targeted CAR-T cell therapies represented a potential growth area. CAR-T therapy is a rapidly evolving field with significant potential for treating certain types of cancer. However, Humanigen's ability to capitalize on this opportunity is now uncertain due to the bankruptcy.
- RAS Pathway Mutations: Studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations could have opened up a new market for the drug. This is a specific subset of patients with a high unmet need. However, the company's ability to pursue this research is now uncertain due to the bankruptcy.
Opportunities
- Successful reorganization and securing funding.
- Potential for lenzilumab in other inflammatory conditions.
- Partnerships and collaborations.
- Advancements in CAR-T therapy.
Threats
- Failure to reorganize and emerge from bankruptcy.
- Competition from other biotechnology companies.
- Regulatory hurdles.
- Patent expiration.
Competitive Advantages
- Proprietary Humaneered antibody technology.
- Patent protection for lenzilumab and other drug candidates (uncertain due to bankruptcy).
- Clinical data supporting the efficacy of lenzilumab (uncertain value due to bankruptcy).
- Expertise in immunology and drug development.
About HGENQ
Humanigen, Inc., founded in 2000 and headquartered in Short Hills, New Jersey, is a clinical-stage biopharmaceutical company dedicated to preventing and treating immune hyper-response. The company's primary focus has been the development of lenzilumab, a Humaneered monoclonal antibody designed to bind to and neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF). Lenzilumab was being investigated as a treatment for cytokine storm associated with COVID-19, with a completed Phase 3 study and participation in a Phase 2/3 study sponsored by the NIH. Humanigen also explored lenzilumab's potential in other inflammatory conditions, including acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis, as well as chronic myelomonocytic leukemia exhibiting RAS pathway mutations. The company's pipeline also includes ifabotuzumab, targeting EphA3, and HGEN005, targeting EMR1, for treating eosinophilic diseases. However, on January 3, 2024, Humanigen filed for Chapter 11 bankruptcy, introducing significant uncertainty to its operations and future prospects.
What They Do
- Develop Humaneered monoclonal antibodies.
- Focus on preventing and treating immune hyper-response.
- Develop lenzilumab to neutralize GM-CSF.
- Target cytokine storm associated with COVID-19.
- Explore lenzilumab for Graft versus Host Disease.
- Investigate lenzilumab for eosinophilic asthma and rheumatoid arthritis.
- Study lenzilumab for chronic myelomonocytic leukemia.
Business Model
- Develop and commercialize biopharmaceutical products.
- Focus on research and development of novel therapies.
- Seek regulatory approval for their drug candidates.
- Potentially out-license or partner for commercialization.
Industry Context
Humanigen operates within the biotechnology industry, a sector characterized by high risk and high reward. The industry is driven by innovation in drug development and the pursuit of treatments for unmet medical needs. Competition is intense, with companies like CTBO, DGCRF, GLSHQ, GNBT, and NAVB also vying for market share in various therapeutic areas. Humanigen's focus on immune hyper-response placed it in a competitive landscape with companies developing therapies for inflammatory and autoimmune diseases. However, its Chapter 11 filing distinguishes it from its peers, adding a layer of complexity and uncertainty to its competitive positioning.
Key Customers
- Patients suffering from immune hyper-response.
- Hospitals and healthcare providers.
- Pharmaceutical companies (potential partners).
- Research institutions (potential collaborators).
Financials
Chart & Info
Humanigen, Inc. (HGENQ) stock price: Price data unavailable
Latest News
No recent news available for HGENQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HGENQ.
Price Targets
Wall Street price target analysis for HGENQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates HGENQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Cameron Durrant MBA
CEO
Cameron Durrant is the CEO of Humanigen, Inc. He has an MBA. His background includes experience in the pharmaceutical and biotechnology industries. He is responsible for managing the company's overall strategy and operations. With only 6 employees, his role is critical to the company's survival and restructuring efforts during the Chapter 11 process.
Track Record: Under Cameron Durrant's leadership, Humanigen focused on developing lenzilumab and advancing its clinical trials. However, the company ultimately filed for Chapter 11 bankruptcy, indicating significant challenges in achieving financial stability and commercial success. His track record is now closely tied to the outcome of the bankruptcy proceedings.
HGENQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements. This tier is considered highly speculative due to the lack of regulatory oversight and the potential for fraud or manipulation. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Uncertainty regarding the company's financial viability.
- Verify the company's financial statements (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Confirm the company's registration and compliance status.
- Existence of a website and contact information.
- Publicly available press releases or news articles (if any).
- Registration with the SEC (if applicable).
- Independent audit of financial statements (if available).
- Active engagement with investors (if any).
What Investors Ask About Humanigen, Inc. (HGENQ)
What does Humanigen, Inc. do?
Humanigen, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune hyper-response. Its primary focus was on lenzilumab, a Humaneered monoclonal antibody designed to neutralize GM-CSF, with potential applications in treating cytokine storm associated with COVID-19 and other inflammatory conditions. However, the company filed for Chapter 11 bankruptcy in January 2024, casting uncertainty on its future operations and the development of its pipeline.
What do analysts say about HGENQ stock?
Given Humanigen's Chapter 11 bankruptcy filing, traditional analyst ratings and price targets are largely irrelevant. The stock's value is now primarily driven by the potential for a successful reorganization and the recovery of value for creditors and shareholders. Any prior analyst consensus should be viewed with extreme caution, as the company's financial situation has fundamentally changed.
What are the main risks for HGENQ?
The primary risk for HGENQ is the Chapter 11 bankruptcy process. There is a significant risk that the company will not be able to successfully reorganize and emerge from bankruptcy, potentially leading to a complete loss of investment for shareholders. Other risks include the potential for dilution of existing shareholders, loss of key personnel, and regulatory setbacks. Investing in HGENQ is highly speculative and carries substantial risk.
What are the key factors to evaluate for HGENQ?
Humanigen, Inc. (HGENQ) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary Humaneered antibody technology.. Primary risk to monitor: Ongoing: Chapter 11 bankruptcy.. This is not financial advice.
How frequently does HGENQ data refresh on this page?
HGENQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HGENQ's recent stock price performance?
Recent price movement in Humanigen, Inc. (HGENQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Humaneered antibody technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HGENQ overvalued or undervalued right now?
Determining whether Humanigen, Inc. (HGENQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HGENQ?
Before investing in Humanigen, Inc. (HGENQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete or inaccurate due to the company's bankruptcy proceedings.
- The analysis is subject to change based on new information or developments in the bankruptcy process.